(Q37087947)

18 August 2017

1 reference

title

Prostate cancer: genes, environment, immunity and the use of immunotherapy (English)

1 reference

18 August 2017

1 reference

1 reference

D Karan

1

1 reference

18 August 2017

J B Thrasher

series ordinal

2

1 reference

18 August 2017

D Lubaroff

series ordinal

3

1 reference

18 August 2017

publication date

19 February 2008

1 reference

Prostate Cancer and Prostatic Diseases

18 August 2017

published in

1 reference

18 August 2017

volume

11

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

230-236

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2008.3

18 August 2017

exact match

0 references

cites work

Development of cancer vaccine by tumor rejection antigens

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Mechanisms of disease: the developmental origins of disease and the role of the epigenotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

The epidemiology of second primary cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Immunosuppressive factors: role in cancer development and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Interleukin-10 and the immune response against cancer: a counterpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Diet, lifestyle and risk of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Impact of diet on prostate cancer: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Epidemiology — identifying the causes and preventability of cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Summary of the evidence: Occupation and environment and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Selenium/cadmium ratios in human prostates: indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective effects of selenium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Unfairness and health: evidence from the Whitehall II Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Current status of the molecular genetics of human prostatic adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Small dsRNAs induce transcriptional activation in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

miRNAs and apoptosis: RNAs to die for.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

miRNA: licensed to kill the messenger

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

MicroRNAs in biological processes and carcinogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

MicroRNA biogenesis, functionality and cancer relevance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

31 March 2020

MicroRNAs and cancer.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

MicroRNA expression and function in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

microRNAs as oncogenes and tumor suppressors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

MicroRNA expression profiling in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Environment and cancer: who are susceptible?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Why Old McDonald had a farm but no allergies: genes, environments, and the hygiene hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Hay fever, hygiene, and household size

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Inflammation in prostate carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Dysregulated expression of MIC-1/PDF in human prostate tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Cyclooxygenase-2 promotes prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Tumor escape mechanisms in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

RNA as a tumor vaccine: a review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Tumor Vaccine Design: Concepts, Mechanisms, and Efficacy Testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Cancer vaccines as a therapeutic modality: The long trek

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Immunotherapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Immunotherapy and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Prostate cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Dendritic cells in vaccination therapies of malignant diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

CpG motifs: the active ingredient in bacterial extracts?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

CpG motifs in bacterial DNA trigger direct B-cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Toll-like receptors in innate immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Therapeutic potential of Toll-like receptor 9 activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Development of TLR9 agonists for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Immunotherapeutic uses of CpG oligodeoxynucleotides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Adenovirus-mediated in vivo gene transfer and expression in normal rat liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

CD8+ T-Cell Tolerance can be Broken by an Adenoviral Vaccine While CD4+ T-Cell Tolerance is Broken by Additional Co-administration of a Toll-Like Receptor Ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

Cancer. Cancer immunotherapy is more than a numbers game.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.3

31 March 2020

Identifiers

DOI

10.1038/PCAN.2008.3

1 reference

18 August 2017

1 reference